Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection)
Overview
- Phase
- Phase 1
- Intervention
- ranibizumab injection (0.5 mg)
- Conditions
- Coats' Disease
- Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Enrollment
- 18
- Locations
- 2
- Primary Endpoint
- Safety and tolerability of intravitreal injections of ranibizumab in the treatment of non-AMD variants and other CNV related conditions
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of intravitreal injections of ranibizumab in the treatment of AMD variants and other choroidal neovascularization (CNV) related conditions (Coats' disease, idiopathic perifoveal telangiectasia, retinal angiomatous proliferation, polypoidal vasculopathy, pseudoxanthoma elasticum, pathological myopia, multi-focal choroiditis, rubeosis iridis) using the incidence and severity of adverse events.
Limited forms of treatment are available that limit the loss of visual acuity. However, the patients may not have any substantial improvement in acuity or function. Therefore there remains a significant unmet need for therapeutic options managing the neovascularization and its consequences.
Lucentis (ranibizumab) injection will be considered as an attempt to control the growth of the abnormal vessels because of evidence suggesting that angiogenic factors, such as vascular endothelial growth factor (VEGF), play a role in the pathogenesis of neovascular non-AMD conditions.
The rationale for the study design is as follows:
A 0.5 mg dose of Lucentis (ranibizumab), a commercially available preparation that is Food and Drug Administration (FDA) approved and labeled for intravitreal injection use for neovascular (wet) age-related macular degeneration will be used.
In AMD variants and other CNV related conditions, vascular endothelial growth factor (VEGF) plays a role in the pathogenesis as in neovascular AMD.
Intravitreal injection of ranibizumab delivers maximal concentration of the antibody fragment to the vitreous cavity with minimal systemic exposure. The dosing schedule, based on considerations of the half-life and the clinical response in patients with neovascularization suggests that a 1-month interval is optimal.
Investigators
Joan
Lawrence A. Yannuzzi, M.D.
Manhattan Eye, Ear & Throat Hospital
Eligibility Criteria
Inclusion Criteria
- •Subjects will be eligible if the following criteria are met:
- •Ability to provide written informed consent and comply with study assessments for the full duration of the study
- •Age \> 18 years
- •Clinical diagnosis of the following conditions: Coats' disease, idiopathic perifoveal telangiectasia, retinal angiomatous proliferation, polypoidal vasculopathy, pseudoxanthoma elasticum, pathological myopia, multi-focal choroiditis, rubeosis iridis.
- •Visual acuity of 20/40 to 20/320 in the study eye on the ETDRS visual acuity chart.
- •Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography
Exclusion Criteria
- •Subjects who meet any of the following criteria will be excluded from this study:
- •Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy is initiated
- •Participation in another simultaneous medical investigation or trial
- •Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
- •Patients who have undergone intraocular surgery within the last 2 months.
- •Patient participating in any other investigational drug study.
- •Use of an investigational drug or treatment related or unrelated to the patient's condition within 30 days prior to receipt of study medication (verteporfin, pegaptanib, or other AMD therapy in the study eye)
- •Patient treated with systemic anti-VEGF or pro-VEGF agents within 3 months before enrollment.
- •Previous treatment (in either eye) with intravitreal or intravenously administered Avastin (bevacizumab).
- •Inability to obtain photographs to document CNV (including difficulty with venous access).
Arms & Interventions
(Ranibizumab) Lucentis
(Ranibizumab)Lucentis 0.5%
Intervention: ranibizumab injection (0.5 mg)
Outcomes
Primary Outcomes
Safety and tolerability of intravitreal injections of ranibizumab in the treatment of non-AMD variants and other CNV related conditions
Time Frame: 24 months
Secondary Outcomes
- Mean change in central retinal thickness as measured by OCT at month 12 compared to baseline(24 months)
- Change in leakage area seen during fluorescein angiography at month 12 as compared with baseline(24 months)
- Number of additional injections required following the initial 3 injections(24 months)